Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation
Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation
复制标题
DOI：
10.1016/j.jpba.2016.02.026
复制
发表时间：
2016-05-30
影响因子：
3.4
通讯作者：
Mahdi, Abbas Ali
中科院分区：
文献类型：
--
作者：
Bansal, Navneeta;Gupta, Ashok Kumar;Mahdi, Abbas Ali
膀胱癌（BC）是全球第五大常见癌症，死亡率惊人。尿细胞学检查和膀胱镜检查的缩短以及存活率的稀疏改善促使我们发展基于替代血清的蛋白质生物标志物以在早期阶段识别BC。先前，我们显示与健康对照（HC）相比，术前BC血清中S100 A4、S100 A8、S100 A9、碳酸酐酶I（CA I）和膜联蛋白V蛋白的异常表达（Clin Chim Acta，2014; 36：97-103）。在这里，我们进一步评估和验证这些结果与随访术后BC患者。本研究对160份血清样本进行，包括健康对照（HC，n = 52）、术前（n = 55）和术后（n = 53）BC患者。采用酶联免疫吸附试验（ELISA）鉴定异常表达蛋白。ELISA结果显示，与术前BC血清样品相比，S100 A8、S100 A9、S100 A4和CA I的表达水平逐渐且显著降低;同时，Annexin V在术后逐渐且显著增加。血清蛋白生物标志物似乎是BC识别和预测患者结果的一种令人鼓舞且侵入性最小的方法。(C)2016爱思唯尔B. V.保留所有权利。
Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes. (C) 2016 Elsevier B.V. All rights reserved.